BTIG Maintains Buy on Absci, Raises Price Target to $16
BTIG analyst Kambiz Yazdi maintains Absci (NASDAQ:ABSI) with a Buy and raises the price target from $13 to $16.
Stocks · News reference
Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BTIG analyst Kambiz Yazdi maintains Absci (NASDAQ:ABSI) with a Buy and raises the price target from $13 to $16.
Twist Bioscience joins Eli Lilly's TuneLab platform, supplying high-throughput antibody data to train advanced AI drug prediction models.
Shares of Eli Lilly and Company are trading higher Tuesday following positive previews of its late-stage obesity and diabetes pipeline.
The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.